UK NICE recommended rejecting Gilead’s Trodelvy treatment for triple-negative breast cancer
- A Single US$2.15-Million Injection to Block 90% of Cancer Cell Formation
- WIV: Prevention of New Disease X and Investigation of the Origin of COVID-19
- Why Botulinum Toxin Reigns as One of the Deadliest Poisons?
- FDA Approves Pfizer’s One-Time Gene Therapy for Hemophilia B: $3.5 Million per Dose
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
UK NICE recommended rejecting Gilead’s Trodelvy treatment for triple-negative breast cancer
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
UK NICE recommended rejecting Gilead’s Trodelvy treatment for triple-negative breast cancer due to high price
Last week, NICE, the UK’s drug price watchdog, released draft guidelines recommending rejecting Gilead’s Trodelvy for triple-negative breast cancer, saying the drug was too expensive for the UK’s National Health Service.
After the draft guidance was released, there was a three-week public comment period, and NICE put the onus on Gilead for lowering the price of Trodelvy.
It is reported that compared with chemotherapy, Trodelvy has been shown to prolong the lives of patients with triple negative breast cancer (TNBC).
NICE estimates there are 2,000 women with triple-negative breast cancer in the UK, 650 of whom are eligible for Trodelvy after approval. Currently, NICE has recommended the use of Roche’s Tecentriq in combination with chemotherapy for triple-negative breast cancer.
Gilead expressed disappointment at the decision and said the UK was the only country in the ORBIS project that did not reimburse the drug.
In September 2020, Gilead acquired Immunomedics for $21 billion and acquired its drug Trodelvy, which is also the largest acquisition in the pharmaceutical industry in 2020.
Gilead said of the decision that the company will work with NICE to resolve issues surrounding cost-effectiveness and seek to reach an agreement by May 10.
Additionally companies have made a cost-effective case for SG reimbursement in England and are concerned about unnecessary delays. In the case of Trodelvy, there are certain differences between the guideline and the Scottish standard as Scotland has already approved Trodelvy.
In another decision worth noting, NICE last week also rejected three atopic dermatitis drugs — AbbVie’s Rinvoq, Pfizer’s Cibinqo and Leo Pharma’s Adtralza. NICE said there was uncertainty about the efficacy of the drugs compared to other approved topical treatments, such as creams and corticosteroids, and said the decision would not affect patients already on the drug.
Reference:
NICE tells Gilead to cut Trodelvy’s price and rejects eczema meds from AbbVie, Pfizer and Leo
UK NICE recommended rejecting Gilead’s Trodelvy treatment for triple-negative breast cancer
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
